Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab DOI Creative Commons
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 14, 2025

Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, sex hormonal profile, intrinsic differences local systemic immune systems urobiome composition. Existing literature data pan-cancer context reveal contradictory results, real-world evidence urothelial carcinoma (UC) is lacking. This was real-world, multicenter, international, observational study determine the effects on clinical outcomes metastatic (mUC) patients progressing or recurring after platinum-based therapy treated pembrolizumab as part routine care. A total 1039 patients, from January 1st, 2016 December 31st, 2023 68 cancer centers were included. Our showed that women had shorter OS than men, 13% advantage 5-year rate for male patients. deeper understanding these results may inform sex-stratification future prospective trials help develop strategies reduce magnitude observed outcomes.

Language: Английский

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab DOI Creative Commons
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 14, 2025

Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, sex hormonal profile, intrinsic differences local systemic immune systems urobiome composition. Existing literature data pan-cancer context reveal contradictory results, real-world evidence urothelial carcinoma (UC) is lacking. This was real-world, multicenter, international, observational study determine the effects on clinical outcomes metastatic (mUC) patients progressing or recurring after platinum-based therapy treated pembrolizumab as part routine care. A total 1039 patients, from January 1st, 2016 December 31st, 2023 68 cancer centers were included. Our showed that women had shorter OS than men, 13% advantage 5-year rate for male patients. deeper understanding these results may inform sex-stratification future prospective trials help develop strategies reduce magnitude observed outcomes.

Language: Английский

Citations

0